Protagonist Therapeutics Inc (PTGX)
Healthcare
Biotechnology
136.60 $
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Protagonist Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 20 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Breakout & Setup
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
8.8$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
64Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
81.6%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
1.8
Performance
Perf. 1M
Price performance over the last month.
21.10%
Perf. 3M
Price performance over the last 3 months.
22.90%
Perf. 6M
Price performance over the last 6 months.
36.90%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
36.20%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-2.8%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
27.9
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
–
P/B
Price-to-book ratio: market value relative to book equity.
13.4
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
118.4
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
244.6
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
–
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
100.0%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
-6.5%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
-154.9%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-17.1%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-12.4%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
94.0%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
0.02
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
21.79
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
6 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
99.00%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
351.30%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
-89.41%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
-68.62%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
-116.40%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
2
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
87
Top 10%
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
94
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
6 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
C (47 out of 100)
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
21.79
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.98 | 348.30 | 171 | 184.40 | 77.20 | -29 | -30 |
| 2025: Q1 | -0.19 | -105.70 | 28 | -88.90 | -41.20 | 125 | 125 |
| 2025: Q2 | -0.55 | – | 6 | 33.10 | -627.00 | -29 | -30 |
| 2025: Q3 | -0.62 | – | 5 | 0.80 | -834.90 | -2 | -2 |
| 2025: Q4 | -0.70 | -135.20 | 7 | -95.60 | -596.80 | -37 | -36 |
| 2026: Q1 | 0.05 | – | 56 | 99.00 | 6.70 | -49 | -49 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Protagonist Therapeutics, Inc. ist ein Forschungs- und Entwicklungsunternehmen in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 131 |
| Headquarters | Newark, CA |
| Website | protagonist-inc.com |
| IPO Date | 11. Aug 2016 |
| Next Earnings | 5. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 1957 |
| Asif Ali | Executive VP & CFO | 1974 |
| Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer | 1959 |
| Venkat Thalladi Ph.D. | EVP & Chief Technical Officer | – |
| Newman Yeilding M.D. | Executive VP, Chief Scientific Officer | – |
| Matthew M. Gosling J.D. | Executive VP and Chief Legal & Business Officer | 1971 |
| Carena Spivey | Executive VP & Chief Human Resources Officer | – |
| Ashok Bhandari Ph.D. | EVP & Chief Discovery Officer | 1964 |
| Carter J. King | Executive Vice President of Business Development | 1971 |
| Abha Bommireddi | Executive VP & Chief of Staff | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20. Apr 2026 | Asif Ali | CFO | Sell | 1,750 | 105.47 | 184,573 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.